Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$76.38 CAD
Change Today -0.36 / -0.47%
Volume 55.0K
CCT On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ GS
Berlin
As of 4:00 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

catamaran corp (CCT) Snapshot

Open
C$76.84
Previous Close
C$76.74
Day High
C$76.84
Day Low
C$75.75
52 Week High
07/2/15 - C$76.95
52 Week Low
10/20/14 - C$44.17
Market Cap
15.9B
Average Volume 10 Days
1.2M
EPS TTM
C$1.68
Shares Outstanding
208.0M
EX-Date
--
P/E TM
36.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for CATAMARAN CORP (CCT)

catamaran corp (CCT) Related Businessweek News

No Related Businessweek News Found

catamaran corp (CCT) Details

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments, PBM and HCIT. The PBM services include electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail and specialty pharmacy claims management, Medicare Part D services, benefit design consultation, preferred drug management programs, drug review and analysis, consulting services, data access, and reporting and information analysis. It owns and operates a network of mail and specialty pharmacies. The HCIT solutions include RxCLAIM, an online transaction processing system to provide adjudication of third-party prescription drug claims at the point of service, including claims management and review, as well as payment and billing support and real-time functionality for updating benefit, price, member, provider, and drug details. It also provides RxBUILDER, a Web-based interface for formulary creation and maintenance; RxPORTAL, which allows customers to interact with the patient’s formulary and drug history; and RxAUTH, a prior authorization management solution. In addition, the company offers RxMAX, a rebate management system for assisting health plans in managing their relationships with pharmaceutical manufacturers; Zynchros, which provides a suite of formulary management tools; and RxTRACK, a data warehouse and analysis system. It serves various organizations in the pharmaceutical supply chain, such as federal, provincial, state, and local governments; unions; corporations; pharmacy benefit managers; managed care organizations; retail pharmacy chains; and other healthcare intermediaries. The company was formerly known as SXC Health Solutions Corp. and changed its name to Catamaran Corporation in July 2012. Catamaran Corporation was founded in 1993 and is headquartered in Schaumburg, Illinois.

Founded in 1993

catamaran corp (CCT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.2M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $425.0K
Executive Vice President of Operations
Total Annual Compensation: $700.0K
Executive Vice President of Pharmacy Operatio...
Total Annual Compensation: $475.0K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2014.

catamaran corp (CCT) Key Developments

Robbins Arroyo LLP Files Class Action Lawsuit Against Catamaran Corporation

Robbins Arroyo LLP announced that it filed a class action lawsuit on June 3, 2015, in the U.S. District Court for the Northern District of Illinois, Eastern Division on behalf of the shareholders of Catamaran Corporation against Catamaran and its Board of Directors for, among other things, violations of sections 14(a) and 20(a) of the Securities and Exchange Act of 1934 and U.S. Securities and Exchange Commission Rule 14a-9 promulgated thereunder. The complaint arises out of a March 30, 2015 press release announcing that Catamaran had entered into a definitive merger agreement with UnitedHealth Group Incorporated pursuant to which Catamaran's Board agreed to sell Catamaran to UnitedHealth for $61.50 in cash per Catamaran share. The complaint seeks injunctive relief on behalf of the named plaintiff and all other similarly situated shareholders of Catamaran. The named plaintiff is represented by Robbins Arroyo LLP. The complaint alleges that, in an attempt to secure shareholder approval of the Proposed Transaction, the defendants filed a materially false and misleading Proxy Statement with the U.S. Securities and Exchange Commission in violation of the Exchange Act. The omitted and/or misrepresented information is believed to be material to Catamaran's shareholders' ability to make an informed decision whether to approve the Proposed Transaction.

Catamaran Corporation - Shareholder/Analyst Call

Annual General Meeting

Catamaran Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Catamaran Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's revenue was $5,979,260,000 compared to $4,914,479,000 a year ago. Operating income was $158,960,000 compared to $116,789,000 a year ago. Income before income taxes was $143,465,000 compared to $105,453,000 a year ago. Net income attributable to the company was $86,693,000 compared to $63,445,000 a year ago. Basic and diluted earnings per share attributable to the company were $0.42 compared to $0.31 a year ago. Net cash provided by operating activities was $146,682,000 compared to $135,676,000 a year ago. Purchases of property and equipment were $9,140,000 compared to $12,782,000 a year ago. EBITDA was $214,965,000 compared to $170,850,000 a year ago. Non-GAAP net income attributable to the company was $123,211,000 compared to $103,750,000 a year ago. Non-GAAP diluted earnings per share attributable to the company were $0.59 compared to $0.50 a year ago. Net income attributable to the company increased mainly due to increased revenue as a result of new customer implementations, increased specialty sales and additional income generated as a result of the Salveo acquisition.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCT:CN C$76.38 CAD -0.36

CCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aetna Inc $125.51 USD -3.39
BioScrip Inc $3.40 USD -0.17
Cigna Corp $161.29 USD -0.75
Humana Inc $187.50 USD -5.64
Rite Aid Corp $8.39 USD -0.02
View Industry Companies
 

Industry Analysis

CCT

Industry Average

Valuation CCT Industry Range
Price/Earnings 37.1x
Price/Sales 0.6x
Price/Book 2.4x
Price/Cash Flow 20.6x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CATAMARAN CORP, please visit www.catamaranrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.